Trinity Biotech plc(TRIB)Earnings, Financials & Key Ratios
TRIB•NASDAQ
$0.36
Price updated Jun 27, 2026
AboutTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.Show more
- Revenue$44M-28.9%
- EBITDA-$9M+54.8%
- Net Income-$37M-17.6%
- EPS (Diluted)-2.00-13.0%
- Gross Margin38.57%+10.7%
- EBITDA Margin-19.94%+36.4%
- Operating Margin-26.07%+24.2%
- Net Margin-85.36%-65.3%
TRIB Price & Volume
Trinity Biotech plc (TRIB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Threatens Corporate Solvency
Investment Thesis • Updated 2025Q4
VerdictNegative: The company's precarious financial position is underscored by a TTM net loss exceeding $37M and a current ratio of 0.25
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Insolvency and liquidity risk
"Trinity Biotech faces a precarious outlook characterized by a 30.2% year-over-year revenue decline in 2025Q4 and a deteriorating equity position that has reached a $72.0M deficit. The company's aggressive transition into the competitive CGM market appears hampered by an acute liquidity crisis, evidenced by a current ratio of 0.25 and a reliance on debt that has ballooned to $138.0M. Investors should monitor the firm's ability to stabilize its core diagnostic business, as the current trajectory suggests significant risks to long-term operational viability."
Verdict Logic
which suggests an unsustainable path toward potential insolvency.
TRIB Growth Metrics
Trinity Biotech plc (TRIB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.94%
5 Years-15.56%
3 Years-11.2%
TTM-28.74%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.64%
Return on Capital
10 Years-16.49%
5 Years-34.65%
3 Years-48.99%
Last Year-64.95%
TRIB Recent Earnings
Trinity Biotech plc (TRIB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (30%)
Q3 2026Latest
Jun 16, 2026Metric
Actual
Est
EPS
$0.23+25.8%
$0.31
Rev
—
$11M
Q2 2026
Apr 30, 2026Metric
Actual
Est
EPS
$0.90-181.3%
$0.32
Rev
$11M-26.2%
$15M
Q4 2025
Dec 23, 2025Metric
Actual
Est
EPS
$0.32+37.3%
$0.51
Rev
$14M+35.7%
$11M
Q2 2025
May 15, 2025Metric
Actual
Est
EPS
$1.02-240.0%
$0.30
Rev
$16M-0.9%
$16M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 16, 2026 | $0.23vs $0.31+25.8% | —vs $11M |
| Q2 2026 | Apr 30, 2026 | $0.90vs $0.32-181.3% | $11Mvs $15M-26.2% |
| Q4 2025 | Dec 23, 2025 | $0.32vs $0.51+37.3% | $14Mvs $11M+35.7% |
| Q2 2025 | May 15, 2025 | $1.02vs $0.30-240.0% | $16Mvs $16M-0.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Trinity Biotech plc (TRIB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.36 | $3.75M | -0.18 | -28.87% | -85.36% | — | — | |
| $4.46 | $320.97M | -4.74 | -38.1% | -61.93% | -15.09% | — | |
| $1.86 | $10.88M | -0.43 | — | — | — | — | |
| $95.66 | $2.18B | 37.96 | 13.53% | 24.35% | 16.19% | — | |
| $13.79 | $938.85M | -0.83 | -1.89% | -45.57% | -56.31% | — | |
| $4.48 | $578.56M | -8.62 | 0.52% | -36.25% | -20.77% | — |
Compare TRIB vs Peers
Trinity Biotech plc (TRIB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TRIB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TRIB Frequently Asked Questions
Trinity Biotech plc (TRIB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Trinity Biotech plc's revenue?
Trinity Biotech plc (TRIB) reported $43.9M in revenue for fiscal year 2025. This represents a 509% increase from $7.2M in 1996.
How fast is Trinity Biotech plc growing?
Trinity Biotech plc (TRIB) saw revenue decline by 28.9% over the past year.
Is TRIB profitable?
Trinity Biotech plc (TRIB) reported a net loss of $37.4M for fiscal year 2025.
Dividend & Returns
What is Trinity Biotech plc's free cash flow?
Trinity Biotech plc (TRIB) had negative free cash flow of $6.3M in fiscal year 2025, likely due to heavy capital investments.